BIONTECH SE SPON. ADRS 1
Commented by André Will-Laudien on November 5th, 2024 | 07:30 CET
The tension is rising! Quarterly figures from BioNTech and Evotec – Doubling potential for BioNxt, Grenke and SMCI
The reporting season has just started, and the first profit warnings are already here. Grenke warns of increasing provisions, Super Micro Computer is keen to submit figures, but the auditor has resigned. There is good news, however, from Evotec, BioNTech, and BioNxt, with their bottoming phases seemingly behind them. In an environment of falling interest rates, biotech stocks could now appear in a new light. Currently, everyone is looking west because the world's largest economic power is electing a new president. Once the uncertainty clears, markets may continue their positive trend. We have some interesting investment ideas in store.
Read
Commented by André Will-Laudien on October 24th, 2024 | 07:30 CEST
Biotech – Are takeovers looming amidst curious prices? Evotec, Bayer, Vidac Pharma and BioNTech in the spotlight
The biotech sector is once again in the spotlight. Since the acquisition of MorphoSys at the beginning of the year, the speculation carousel is turning again. Is Evotec next, or maybe Vidac Pharma? The Hamburg-based drug specialist came under fire from short-sellers after the resignation of long-standing CEO Lanthaler, who had shorted over 4% of the capital by mid-September. However, the price stubbornly held above the EUR 5 mark, and yesterday saw a 10% rise to EUR 6.60. What is behind this? Last week, it was Vidac Pharma that surged 300% from a standing start with enormous trading volumes. The thought processes of market participants are evident: interest rates are falling, making refinancing attractive again for upcoming financial investors. We shed light on the key players.
Read
Commented by Armin Schulz on October 23rd, 2024 | 08:00 CEST
Evotec, Nyxoah, BioNTech – Stocks for the future?
The biotechnology and medtech industries are at an exciting turning point, with companies such as Evotec, Nyxoah and BioNTech positioning themselves as leading players in this dynamic field. Their innovative technologies and promising product pipelines could have the potential to fundamentally transform healthcare. Evotec excels in drug discovery expertise, Nyxoah develops groundbreaking solutions for sleep apnea, and BioNTech is a pioneer in mRNA technology. Although Evotec and BioNTech have recently faced challenges, all three companies are well-positioned to benefit from future medical developments.
Read
Commented by Fabian Lorenz on October 9th, 2024 | 07:15 CEST
Biotech comeback and takeover fantasy! BioNTech, Bayer, and Vidac Pharma
Money can be made in biotech shares again! However, investors need to look carefully. While Moderna is at a multi-year low, BioNTech and Vidac Pharma have gained over 50% in just a few months. Is there more to come? The chances are good, as both biotech companies have released promising news. Analysts see a tenfold increase in the case of Vidac Pharma, and the focus on the fight against cancer makes the Company a takeover candidate. The cancer specialist would also be a good fit for Bayer and BioNTech, and the share is still cheap. BioNTech is becoming an investment darling again and is focusing on AI. Bayer has yet to make the leap above EUR 30, and analysts are warning about the upcoming quarterly figures.
Read
Commented by Juliane Zielonka on October 3rd, 2024 | 14:00 CEST
Vidac Pharma, BioNTech, Gerresheimer optimize the value chain - From research to patient
Medical innovation and rapid therapy development are gaining momentum thanks to the use of AI. In this context, companies in the pharmaceutical and biotech industry are relying on groundbreaking technologies and strategies to optimize the value chain from research to patient. Vidac Pharma is researching an innovative approach to fighting cancer by supporting the body's own immune defenses. The Company has now received a patent in the US, granting exclusivity. BioNTech is using AI-powered research to bring innovative therapies to patients more quickly. Gerresheimer is producing advanced packaging solutions for pharmaceuticals that have the potential to improve healthcare significantly. We take a look at current annual reports and value chains.
Read
Commented by André Will-Laudien on September 25th, 2024 | 07:00 CEST
The biotech rally of the century is on the horizon! 150% returns with BioNTech, Pfizer, Nyxoah, Bayer, or Evotec?
The stock market keeps climbing, and now it is moving even faster with a double-whammy interest rate cut from the Fed! In a surprising move, the US Federal Reserve pulls a 0.5% rate cut from its magic hat, boosting market sentiment. Now, it is certain that life will continue in the biotech sector. However, selecting the right stocks remains challenging. With a medium-term focus, paying attention to management quality is important because the recent price declines were too high in some cases. However, some research approaches promise a better future. BioNTech, Pfizer, and Bayer have already bottomed out. Nyxoah and Evotec are now showing the first signs of breaking out after a period of consolidation. What is the short-term outlook?
Read
Commented by Stefan Feulner on September 18th, 2024 | 07:00 CEST
CureVac, Nyxoah, and BioNTech with powerful upward momentum
Last week was another busy week on the world's stock markets. After the brief, painful corrections in August, the DAX and Dow Jones are preparing to return to their old highs. The precious metal gold has already reached these highs with flying colors thanks to the interest rate cut fantasy. The capital-intensive biotechnology sector is also benefiting from the possible interest rate cut, with several companies posting double-digit gains.
Read
Commented by Fabian Lorenz on September 16th, 2024 | 07:00 CEST
Big news at BioNTech! Soon also at Nyxoah? What about Sartorius?
The more than 10% jump in BioNTech's share price at the beginning of the week surprised many investors. Was this the starting signal for a sustained upward trend? The biotech company will publish important data in the coming days. Nyxoah is also getting ready for the big bang. The medical technology company is on the verge of entering the US market with its high-tech product. The Belgian company is fully financed to tap into the world's largest healthcare market. Are Nyxoah shares about to take off? The Sartorius share has started a countermovement in recent days. Is there more to come for the share price?
Read
Commented by Stefan Feulner on September 11th, 2024 | 07:45 CEST
BioNTech, First Hydrogen, and TSMC with big announcements
As we enter the final third of what has so far been a successful 2024 stock market year, uncertainties and volatility are increasing. Even the seemingly invincible chip giant Nvidia has lost around a quarter of its stock market value since its highs in mid-June. On the other hand, other companies that have fallen sharply in recent months have reported positive news that could herald a possible rebound.
Read
Commented by Armin Schulz on September 4th, 2024 | 07:30 CEST
Bayer, Vidac Pharma, BioNTech - Healthcare sector on the verge of a renaissance
Promising signs of a renaissance in the healthcare sector have emerged in recent months. Innovative start-ups are driving the digital transformation forward despite a decline in investment, as evidenced by the Digital Health Radar 2024. In Germany, Federal Health Minister Karl Lauterbach has introduced significant legislative reforms by July 2024, such as the introduction of electronic patient records and e-prescriptions. Complemented by increased M&A activity and technological integration through telehealth and AI, experts anticipate significant long-term growth potential despite the challenges faced in 2023. These developments point to a promising future for the healthcare sector. We take a look at three exciting candidates.
Read